X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs GSK PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD GSK PHARMA MERCK LTD/
GSK PHARMA
 
P/E (TTM) x 52.6 68.0 77.3% View Chart
P/BV x 7.9 13.7 58.0% View Chart
Dividend Yield % 0.4 2.1 16.9%  

Financials

 MERCK LTD   GSK PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
GSK PHARMA
Mar-18
MERCK LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0602,760 38.4%   
Low Rs6232,040 30.5%   
Sales per share (Unadj.) Rs632.4339.0 186.5%  
Earnings per share (Unadj.) Rs45.741.4 110.4%  
Cash flow per share (Unadj.) Rs62.345.9 135.7%  
Dividends per share (Unadj.) Rs11.0035.00 31.4%  
Dividend yield (eoy) %1.31.5 89.6%  
Book value per share (Unadj.) Rs388.8242.9 160.1%  
Shares outstanding (eoy) m16.6084.70 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.37.1 18.8%   
Avg P/E ratio x18.457.9 31.8%  
P/CF ratio (eoy) x13.552.3 25.8%  
Price / Book Value ratio x2.29.9 21.9%  
Dividend payout %24.184.5 28.5%   
Avg Mkt Cap Rs m13,969203,280 6.9%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,4875,234 28.4%   
Avg. sales/employee Rs Th6,631.9NM-  
Avg. wages/employee Rs Th939.2NM-  
Avg. net profit/employee Rs Th479.4NM-  
INCOME DATA
Net Sales Rs m10,49828,715 36.6%  
Other income Rs m242545 44.4%   
Total revenues Rs m10,74129,260 36.7%   
Gross profit Rs m1,1355,059 22.4%  
Depreciation Rs m276380 72.5%   
Interest Rs m02 0.0%   
Profit before tax Rs m1,1025,222 21.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m3431,892 18.1%   
Profit after tax Rs m7593,508 21.6%  
Gross profit margin %10.817.6 61.4%  
Effective tax rate %31.136.2 86.0%   
Net profit margin %7.212.2 59.2%  
BALANCE SHEET DATA
Current assets Rs m6,41021,815 29.4%   
Current liabilities Rs m8,82815,999 55.2%   
Net working cap to sales %-23.020.3 -113.7%  
Current ratio x0.71.4 53.2%  
Inventory Days Days5864 90.7%  
Debtors Days Days3819 205.4%  
Net fixed assets Rs m1,40612,475 11.3%   
Share capital Rs m166847 19.6%   
"Free" reserves Rs m6,28619,726 31.9%   
Net worth Rs m6,45520,573 31.4%   
Long term debt Rs m06 0.0%   
Total assets Rs m8,82839,475 22.4%  
Interest coverage xNM2,612.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 163.5%   
Return on assets %8.68.9 96.7%  
Return on equity %11.817.1 69.0%  
Return on capital %17.126.2 65.1%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m959564 170.0%   
Fx outflow Rs m2,6127,429 35.2%   
Net fx Rs m-1,653-6,865 24.1%   
CASH FLOW
From Operations Rs m1,0704,728 22.6%  
From Investments Rs m-750-1,042 72.0%  
From Financial Activity Rs m-150-3,066 4.9%  
Net Cashflow Rs m171620 27.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 50.7 102.2%  
Indian inst/Mut Fund % 18.2 10.2 178.4%  
FIIs % 1.0 23.8 4.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 15.4 189.0%  
Shareholders   28,591 102,036 28.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - STERLING BIOTECH COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS